Circulating tumor markers in gynecological tumors

Current Opinion in Oncology

Volumn 8, Issue 5, 1996, Pages 426-431

  Rustin, Gordon J S ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN; TUMOR MARKER;

CANCER RECURRENCE; FEMALE GENITAL TRACT TUMOR; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECOND LOOK SURGERY; SQUAMOUS CELL CARCINOMA; TROPHOBLASTIC TUMOR; UTERINE CERVIX CARCINOMA;

EID: 0029914041     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199609000-00015     Document Type: Review

References (51)

1. Clement M, Bischof P, Gruffat C, Ricolleau G, Auvray E, Quillen V, Pacheco C, Torres M, Ferdeghini M: Clinical validation of the new Elsa-CA 125 II assay: report of a European multicentre evaluation. Int J Cancer 1995, 60:199-203.
2. Kenemans P, Veratraeten AA, Van-Kamp GJ, Von-Mensdorff-Pouilly S: The second generation CA 125 assays. Ann Med 1995, 27:107-113.
3. Mogensen O, Mogensen B: Imx CA 125, an automated microparticle enzyme immunoassay: technical characteristics and clinical usefulness after recalibration. Scand J Clin Lab Invest 1995, 55:289-294.
4. Runnebaum IB, Tong XW, Konig R, Zhao-H, Korner K, Atkinson EN, Kreienberg R, Kieback DG, Zhao H: p-53-Based blood test for D53PIN3 and risk for sporadic ovarian cancer. Lancet 1995, 345:994.
5. Campbell IG, Eccles DM, Dunn B, Davis M, Leake V: Polymorphism in ovarian and breast cancer, Lancet 1996, 347:393-394.
6. Berek JS, Martinez-Maza O, Hamilton T, Trope C, Kaern J, Baak J, Rustin GJS: Molecular and biological factors in the pathogenesis of ovarian cancer. Ann Oncol 1993, 4(suppl 4):S3-S16.
7. Tuxen MK, Soletormos G, Dombernowsky P: Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995, 21:215-245. A very comprehensive review, especially of the use of CA 125, CEA, TPA, TATI, CASA, and tetrarectin in the screening, diagnosis, and monitoring of ovarian cancer.
8. Jacobs IJ, Davies AP, Bridges J: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J 1993, 306:1030-1034.
9. Berek JS, Bast RC: The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995, 76(suppl 10):2092-2096. A very good review of the use of complementary markers.
10. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang YC, Bast RC, Knapp • RC: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995, 76(suppl 10):2004-2010. Complicated but important paper showing how serial marker trends can be used to improve sensitivity for screening.
11. Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N: Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumour Biol 1995, 16:345-352.
12. Walker R, Crebbin V, Stern J, Scudder S, Schwartz P: Urinary Gonadotropln Peptide (UGP) as a marker of gynecologic malignancies. Anticancer Res 1994, 14:1703-1710.
13. Jacobs IJ, Jeyarajah AR, Seng-Ji XU, Woolas RP, Davies AP, Oram DH, Bast RC Jr: Combination of markers in screening for ovarian cancer. Int J Gynaecol Obstet 1994, 46(suppl 2):83.
14. Cane P, Azen C, Lopez E, Platt LD, Karlan BY: Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. Gynecol Oncol 1995, 57:240-245. Less than 15% of women had increased levels of LASA, DM-70K, UGP, or HER-2 on both screens, but with CA 125, 15% of women had two increased values.
15. Jacobs I, Oram D: A randomised clinical trial of multimodal and sequential screening for ovarian cancer. Ovarian Cancer Screening Unit, The Royal Hospital Trust, St. Bartholomew's Hospital, London, 1995.
16. Belinson JL, Okin C, Casey G, Ayoub A, Klein R, Hart WR, Franco K, Litt R: The familial ovarian cancer registry: progress report Cleve Clin J Med 1995, 62:129-134.
17. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V: • Preoperative evaluation of D-Dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996, 60:197-202. In this paper, elevated levels of CA 125 and D-dimer gave good specificity for detecting ovarian cancer.
18. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, Romagnolo C, Federghini M, Zucca S, Trio D, Trovo S: Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994, 54:117-123.
19. Antonic J, Rakar S: Colour and pulsed doppler US and tumour marker CA 125 In differentiation between benign and malignant ovarian masses. Anticancer Res 1995, 15:1527-1532.
20. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P: Preoperative CA 125: an independent prognostic factor in patients with stage 1 epithelial ovarian cancer. Obstet Gynecol 1995, 86:259-264. A CA 125 level of greater than 65 U/mL before surgery for stage 1 disease was shown to be the most powerful prognostic factor.
21. Gadducci A, Zola O, Landoni F, Maggino T, Sartori E, Bergamino T, Christofani R: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer results of a multicentric Italian study. Gynecol Oncol 1995, 58:42-47.
22. Gard GB, Houghton CRS: An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994, 53:283-289.
23. Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RCF, Wilkinson P, Cruickshank D, McAllister EJ, Redman CWE, Parker D, Scott IV, Slevin ML, Roulston JE: The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 1993, 3:285-292.
24. Pavlidis NA, Bairaktari E, Kalef-Ezra J, Nicolaides C, Seferiadis C, Fountzilas G: Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients. Int J Biol Markers 1995, 10:75-80.
25. Stenman UH, Alfthan H, Vartiainen J, Lehtovirta P: Markers supplementing CA 125 in ovarian cancer. Ann Med 1995, 27:115-120.
26. Rustin GJS, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskin •• WJ, Mitchell H, Lamber HH: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996, 14:1545-1551. Selects specific percentage decreases in CA 125 levels as evidence of response and shows that CA 125-defined response correlates well with standard response criteria.
27. Rustin GJS, Crawford M, Lambert J, Ledermann J, Coleman R, Meely K: Trial of oral hexalen for relapsed ovarian carcinoma: comparison of CA 125 and EORTC response definitions. Proc Am Soc Clin Oncol 1995, 14:269.
28. Piccart MJ, Rustin GJS, Gore ME, ten Bokkel Huinink W, van Oosterom V, van der Burg M, Nelstrop A, Selleslags J, te Velde A, Wanters J, Kaye SB: Docetaxel in platinum-pretreated patients. In Ovarian Cancer, edn 4. Edited by Frank S, Blackett T, Leake R, Berek J. London Chapman & Hall Medical, 1996:153-163.
29. Morgan RJ, Speyer J, Doroshow JH, Margolin K, Raschko J, Sorich J, Akman S, Leong L, Somlo G, Vasilev S: Modulation of 5-fluorouracil with hose-dose leucovorin calcium: activity in ovarian cancer and correlation with CA 125 levels. Gynecol Oncol 1995, 58:79-85.
30. van Ravenswaay Claasen HH, Fleuren GJ: The influence of combination chemotherapy on antigen expression In ovarian cancer. Gynecol Oncol 1995, 58:16-23. There was minimal change in the expression of several antigens, including CA 125, in tissue obtained before and after chemotherapy.
31. Menzin AW, Kobrin S, Pollak E, Goodman DBP, Rubin SC: The effect of renal function on serum levels of CA 125. Gynecol Oncol 1995, 58:375-377. This paper demonstrates that impaired renal function does not lead to increased CA 125 levels.
32. Rustin GJS, van der Burg MEL, Berek JS: Tumour markers. Ann Oncol 1993, 4:S71-S77.
33. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Group study. Ann Oncol 1996, 7:361-364.
34. Yue K, Bian M, Zhu D, Liu W, Siu S: Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995, 17:128-132.
35. Sliutz G, Tempfer C, Kainz C, Mustafa G, Koelbl H, Biegelmayer CA: Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up ovarian cancer. Anticancer Res 1995, 15:1127-1129.
36. Van der Burgh MEL, van Lend M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995, 332:629-634. This paper demonstrates a survival benefit from interventional debulking surgery.
37. Folk JJ, Botsford M, Musa AG: Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol 1995, 57:178-182.
38. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Sepp RC: Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 1995, 165:875-878.
39. Mead GM on behalf of the IGCCCG: International consensus prognos tic classification for metastatic germ cell tumours treated with platinum based chemotherapy: final report of the international germ cell cancer collaborative group. (IGCCCG). Proc Am Soc Clin Oncol 1995, 14:235. Serum levels of HCG, AFP, and lactate dehydrogenase are crucial components of this prognostic classification.
40. Jobling T, Makers P, Healy DL, MacLachlan V, Burger HG, Quinn M, Rome R, Day AJ: A prospective study on inhibin in granulosa cell tumours of the ovary. Gynecol Oncol 1994, 55:285-289.
41. Pautier P, Bidart JM, Lallou N, Duvillard P, Michel G, Droz JP, Lhomme C: Value of Inhibin as a tumor marker in granulose cell tumors: apropos of 6 new cases treated at the Gustave-Roussy Institute. Bull Cancer (Paris) 1995, 82:557-560.
42. Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS: Inhibin as a marker for ovarian cancer. Br J Cancer 1995, 71:1046-1050.
43. De Bruijn HWA, Hollema H, Willemse PHB, Ten Hoor KA, Boonstra H: Raised serum squamous cell carcinoma antigen levels in malignant transformation of mature cystic ovarian teratoma. Int J Gynecol Cancer 1996, 6:76-79.
44. Suzuki M, Kobayashi H, Sekiguchi I, Konnai K, Terao T, Sato I: Clinical evaluation of squamous cell carcinoma antigen in squamous cell carcinoma arising In mature cystic teratoma of the ovary. Oncology 1995, 52:287-290.
45. Scambia G, Gadducci A, Panici PB, Foti E, Ferdeghini M, Gerrandina G, Amoroso M, Caslellani C, Facchini V, Mancuso S: Combined use of CA 125 and CA15-3 in patients with endometrial carcinoma. Gynecol Oncol 1994, 54:292-297.
46. Takeshina N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, Yamauchi K, Hasumi K: Combined assay of serum levels of CA 125 and CA19-9 in endometrlal carcinoma. Gynecol Oncol 1994, 54:321-326.
47. Hakala A, Kacmski BM, Stanley ER, Kohorn EI, Puistola U, Risteli J, Risteli L, Tomas C, Kauppila A: Macrophage colony-stimulating factor 1, a clinically useful tumor marker In endometrlal adenocarcinoma: comparison with CA 125 and the amlnoterminal propeptlde of type III procollagen. Am J Obstet Gynecol 1995,173:112-119.
48. Sproston ARM, Roberts SA, Davidson SE, Hunter RD, West CML: Serum tumour markers In carcinoma of the uterine cervix and outcome following radiotherapy. Br J Cancer 1995, 72:1536-1540. In this paper, elevated levels of CA 125, SCC, and TPA at diagnosis are associ-ated with worse prognosis.
49. Carter PG, lies RK, Nevens P, Ind TEJ, Shepherd IH, Chard T: • Measurement of urinary beta core fragment of human chorionk gonadotrophin in women with vulvovaginal malignancy and its prognostic significance. Br J Cancer 1995, 72:350-353. Urinary beta core fragment of HCG is shown to be of prognostic importance in vulvovaginal cancers in addition to previous reports of its value in cervical carcinoma.
50. Tyrey L: Human chorlonic gonadotropln: properties and assay methods. Semin Oncol 1995, 22:121 -129.
51. Vasilev SA, Schlaerth JB, Ahn C, Sauer MV: Serum progesterone monitoring in post-molar surveillance. Gynecol Oncol 1994, 54:288-291.